IBO — Impact BioMedical, Inc.

Impact BioMedical, Inc. (IBO) is a biotechnology company listed on NYSE MKT. It is led by Frank D. Heuszel Esq., J.D., based in 1400 Broadfield Blvd., Houston, TX, United States, 77084, with about 2 employees. Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.

Latest reported IBO revenue for 2025-09-30 was $18.0K. Net income was -$1.5M. Revenue was up 157.1% from 2025-06-30 to 2025-09-30. IBO currently screens at market cap $7.6M.

Use this IBO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IBO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IBO SEC filings page. Lician reads the product cache first so this HTML stays unique to Impact BioMedical, Inc. even when a live quote feed is slow.